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The airway mycobiome in bronchiectasis is associated with clinically significant disease
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ABSTRACT Understanding the composition and clinical importance of the fungal mycobiome was
recently identified as a key topic in a “research priorities” consensus statement for bronchiectasis.
Patients were recruited as part of the CAMEB study: an international multicentre cross-sectional Cohort
of Asian and Matched European Bronchiectasis patients. The mycobiome was determined in 238 patients by
targeted amplicon shotgun sequencing of the 18S–28S rRNA internally transcribed spacer regions ITS1 and
ITS2. Specific quantitative PCR for detection of and conidial quantification for a range of airway Aspergillus
species was performed. Sputum galactomannan, Aspergillus specific IgE, IgG and TARC (thymus and
activation regulated chemokine) levels were measured systemically and associated to clinical outcomes.
The bronchiectasis mycobiome is distinct and characterised by specific fungal genera, including
Aspergillus, Cryptococcus and Clavispora. Aspergillus fumigatus (in Singapore/Kuala Lumpur) and Aspergillus
terreus (in Dundee) dominated profiles, the latter associating with exacerbations. High frequencies of
Aspergillus-associated disease including sensitisation and allergic bronchopulmonary aspergillosis were
detected. Each revealed distinct mycobiome profiles, and associated with more severe disease, poorer
pulmonary function and increased exacerbations.
The pulmonary mycobiome is of clinical relevance in bronchiectasis. Screening for Aspergillus-associated
disease should be considered even in apparently stable patients.
This article has supplementary material available from erj.ersjournals.com
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Introduction
Bronchiectasis is a chronic respiratory disease characterised by progressive bronchial dilatation. To date, no
therapy has been licensed for its treatment. Geographic regions illustrate preponderance for particular
aetiologies, e.g. post-tuberculous disease in countries of endemic infection [1]. Incipient infection in
bronchiectasis incites deleterious host inflammatory responses and disease progression. A “vicious cycle”
of impaired mucociliary clearance, recurrent infection and chronic inflammation, with established links to
bacteria, leads to progressive disease; however, the role of fungi is poorly understood.
The pulmonary microbiome and its association with chronic respiratory disease is an emerging area of
research. Culture-independent airway sequencing has revealed novel associations between the airway
microbiome and lung disease [2]. To date, most airway microbiome studies have a bacterial focus, an
approach that provides disease insight into pathogenesis and prognosis [3, 4]. In contrast, however,
sequencing of the fungal microbiome (the mycobiome) has lagged behind and is applied in relatively few
studies, and to the best of our knowledge, none in bronchiectasis [5].
Fungal spores are environmentally ubiquitous and hence their inhalation is an inevitable consequence of
breathing [6]. While prompt mucociliary and phagocytic clearance occurs in the healthy lung,
anatomically abnormal and immunocompromised airways such as in bronchiectasis are at higher risk of
fungal acquisition, colonisation and potential disease [6]. Our group and others have performed extensive
work characterising fungi in cystic fibrosis (CF)-related bronchiectasis where they colonise and act as
pathogens associated with poorer clinical outcome [7–10].
Fungi, particularly Aspergillus spp., cause a range of pulmonary consequences, including allergic, chronic
and/or invasive disease [11, 12]. An overzealous host response to Aspergillus, for instance, is clinically
important in severe asthma with fungal sensitisation, chronic obstructive pulmonary disease (COPD) and
CF [13–15]. The role of fungi in bronchiectasis not due to CF is, however, less well defined. Aspergillus
sensitisation and/or allergic bronchopulmonary aspergillosis (ABPA) is a cause (∼10%) and, importantly, a
consequence of bronchiectasis [6, 10, 16]. The role of the mycobiome in bronchiectasis is yet to be
comprehensively investigated, and its importance and relevance is clearly highlighted as a priority research
area in this field [17].
We characterise for the first time the mycobiome in bronchiectasis, assessing its clinical relevance in two
geographically distinct cohorts from the CAMEB study, encompassing four Asian sites across Singapore/
Kuala Lumpur and a single European site in Dundee.
Materials and methods
Study population
Patients with stable bronchiectasis were recruited across three countries as part of the CAMEB study, a
cross-sectional Cohort of Asian and Matched European Bronchiectasis. Recruitment included three sites in
Singapore (Singapore General Hospital, Changi General Hospital and Tan Tock Seng Hospital (n=124)),
one Malaysian site (UKM Medical Centre, Kuala Lumpur (n=14)), and an age-, sex- and disease
severity-matched group from a single European site (Ninewells Hospital, Dundee, UK (n=100)), and was
conducted between March 2016 and July 2017. Full details on patient inclusion and exclusion criteria,
nondiseased controls, and the CAMEB population are provided in the supplementary material. Clinical
characteristics, bronchiectasis aetiology and patient demographics are shown in table 1. The study was
approved by the institutional review boards of all participating institutes and all patients gave written
informed consent to participate. Further details are given in the supplementary material.
Methods
Full details on clinical data and specimen collection, statistical analysis, and molecular methods, including
mycobiome analyses, sputum quantitative PCR (qPCR) detection of fungi and immunological bioassays,
are provided in the supplementary material.
Results
The pulmonary mycobiome in bronchiectasis is distinct
Culture-independent analysis of the pulmonary mycobiome in bronchiectasis reveals that Ascomycota
dominate the airway at the phylum level (p<0.01, Mann–Whitney U-test) (figure 1). Fungal diversity was
significantly lower in bronchiectasis, as measured by the number of identified taxa (p<0.01) and the
Shannon diversity index (p<0.05, Mann–Whitney U-test) (figure 1). Limitations of fungal internally
transcribed spacer (ITS) databases may account for the lower classification percentages observed (95.3%)
compared with bacteria, where genus-level operational taxonomic unit classification of ∼99% can be
achieved [19]. Despite Ascomycota dominating overall mycobiome profiles, a significant number of
bronchiectasis patients (49% (n=116)) harboured some degree of airway Basidiomycota. 10% (n=23) had
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TABLE 1 Demographics of the study population including nondiseased (healthy) controls and stable bronchiectasis patients
comprising Asian and European matched cohorts
Nondiseased
controls
Bronchiectasis
patients
Bronchiectasis
patients SG/KL
Matched cohorts
SG/KL Dundee
Subjects 10 238 138 100 100
Age years 37 (30–49) 68 (64–71) 65 (58–73) 65 (58–74) 69 (64–76)
Sex
Female 4 (40) 130 (55) 77 (55) 59 (59) 53 (53)
Male 6 (60) 108 (45) 61 (45) 41 (41) 47 (47)
Aetiology
Idiopathic 145 (61) 85 (62) 63 (63) 60 (60)
Post-infection 56 (23.5) 43 (31) 27 (27) 27 (27)
Other 37 (15.5) 10 (7) 10 (10) 13 (13)
Smoking status
Never-smoker 170 (70) 108 (78) 80 (80) 62 (62)
Current smoker 11 (5) 7 (5) 4 (4) 4 (4)
Ex-smoker 57 (25) 23 (17) 16 (16) 34 (34)
BSI status
Severe 147 (62) 84 (61) 63 (63) 63 (63)
Moderate 71 (30) 45 (33) 26 (26) 26 (26)
Mild 20 (8) 9 (6) 11 (11) 11 (11)
BSI score 9 (6–13) 10 (7–14) 10 (7–14) 9 (6–12)
BMI kg·m−2 24 (22–24) 21 (18–27) 19 (17–22) 19 (17–22) 27 (22–31)
MRC dyspnoea score
1–3 200 (84) 121 (88) 90 (90) 79 (79)
4 26 (11) 10 (7) 6 (6) 16 (16)
5 12 (5) 7 (5) 4 (4) 5 (5)
FEV1 % pred 74 (54–87) 69 (51–84) 69 (52–84) 76 (57–96)
Radiological severity
1–2 lobes involved 106 (45) 62 (45) 43 (43) 44 (44)
⩾3 lobes involved 132 (55) 76 (55) 57 (57) 56 (56)
Exacerbations in previous year
0 84 (35) 69 (50) 44 (44) 15 (15)
1–2 82 (35) 51 (37) 41 (41) 31 (31)
⩾3 72 (30) 18 (13) 15 (15) 54 (54)
Hospital admissions before study
Yes 88 (37) 63 (46) 43 (43) 25 (25)
No 150 (63) 75 (54) 57 (57) 75 (75)
Colonisation with other organisms
Yes 127 (53) 60 (43) 44 (44) 67 (67)
No 111 (47) 78 (57) 56 (56) 33 (33)
Pseudomonas colonisation
Yes 23 (10) 18 (13) 15 (15) 5 (5)
No 215 (90) 120 (87) 85 (85) 95 (95)
Bronchodilator use
Yes 107 (45) 58 (42) 39 (39) 49 (49)
No 131 (55) 80 (58) 61 (61) 51 (51)
Inhaled corticosteroids
Yes 80 (34) 21 (15) 14 (14) 59 (59)
No 158 (66) 117 (85) 86 (86) 41 (41)
Mucolytics
Yes 118 (50) 60 (44) 45 (45) 13 (13)
No 120 (50) 78 (56) 55 (55) 87 (87)
Long-term antibiotics
Yes 48 (20) 22 (16) 14 (14) 26 (26)
No 190 (80) 116 (84) 86 (86) 74 (74)
Data are presented as n, median (interquartile range) or n (%). SG/KL: Singapore/Kuala Lumpur; BSI: Bronchiectasis Severity Index; BMI: body
mass index; MRC: Medical Research Council; FEV1: forced expiratory volume in 1 s. Patients in the matched cohorts were matched on age, sex
and disease severity according to the BSI. The variables defining the composite BSI score, including BMI, shortness of breath (MRC) dyspnoea
score, FEV1 % pred, radiological severity, number of exacerbations in the preceding year defined by established consensus [18], hospitalisations
in the preceding year, microbial colonisation with other organisms and colonisation by Pseudomonas aeruginosa, are also reported.
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Basidiomycota making up at least a quarter of their overall profile, while 4% (n=9) exhibited
Basidiomycota-dominant profiles (figure 2a). Candida, Saccharomyces and Penicillium were the most
frequently detected genera in both groups, while differentially abundant, bronchiectasis-associated genera
included Aspergillus, Cryptococcus, Clavispora, Botrytis and Alternaria (figures 2b and 3a).
In the design of the CAMEB study, n=100 Asian patients (Singapore/Kuala Lumpur) were matched
individually to patients from a European cohort (Dundee) by age, sex and total Bronchiectasis Severity
Index (BSI) score (table 1). This allowed assessment of findings in two geographically distinct cohorts as
well as providing insight into potential regional differences in the bronchiectasis mycobiome. Geographic
variation in mycobiome signature was detected (figure 3a). Patients from Singapore/Kuala Lumpur
exhibited significant and higher average relative abundances of Simplicillium, Trichosporon and Aspergillus,
while patients from Dundee were distinguished by higher abundances of Wickerhamomyces, Clavispora
and Cryptococcus (p<0.05) following assessment of group differences using metastats statistical analysis [20].
Candida, by far the most frequently observed fungal genera, was observed across both cohorts at
equal frequency, while patients from Dundee exhibited higher Saccharomyces, Penicillium, Cryptococcus,
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FIGURE 2 The pulmonary mycobiome in stable bronchiectasis: a) individual patient phylum-level classification
of the pulmonary mycobiome in stable bronchiectasis (n=238) illustrating the relative abundance of
Ascomycota versus Basidiomycota for individual patients, and b) percent prevalence of the top fungal genera
(present at >1% relative abundance) in nondiseased (healthy) controls (n=10) and patients with stable
bronchiectasis (n=238).
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Clavispora and Botrytis in particular. The only fungal genus in the top 10 with higher prevalence in
Singapore/Kuala Lumpur was Aspergillus, although this was detected at all the sampled sites (figure 3b).
Given our identification of Aspergillus as an exclusive bronchiectasis-associated fungal genus with high
airway abundance and its established pathogenic role in other chronic respiratory diseases [10, 12, 13, 15],
we pursued it for further investigation.
Aspergillus fumigatus and Aspergillus terreus are identified in bronchiectasis and associate
with exacerbations
We next further characterised the presence of specific Aspergillus species in the airway by qPCR using
established protocols published by our group and others [7, 21]. We assessed four major Aspergillus
species (A. fumigatus, A. terreus, A. flavus and A. niger) and found that nondiseased individuals had no
detectable airway Aspergillus, in agreement with our mycobiome analysis (figure 4a). In contrast, high
proportions of bronchiectasis patients (from all sites) had detectable A. fumigatus and/or A. terreus, with
no patient demonstrating A. flavus or A. niger (figure 4a). Interestingly, similar proportions of those
recruited from an Asian site had either A. fumigatus and/or A. terreus, while patients from Dundee
demonstrated higher A. terreus (figure 4a), which associates with increased exacerbations (figure 4b).
Importantly, significant numbers of patients (40% (n=96)) harboured both species concurrently. Of these,
an equal distribution between groups recruited from Singapore/Kuala Lumpur and Dundee was observed
(44% versus 52%; p=0.22) (figure 4c). Patients from Singapore/Kuala Lumpur were equally likely to have
none, either or both species in their airway, in contrast to patients from Dundee who exhibited a higher
likelihood for A. terreus (figure 4c). More exacerbations were seen in patients with A. terreus alone or
where both species were present compared with those without any fungi or A. fumigatus alone (figure 4d).
Quantification of A. fumigatus to A. terreus conidial burden ratio and associated exacerbations
We next quantified A. fumigatus and A. terreus conidial burden using established protocols published by
our group [7]. Based on the number of conidia per gram of sputum, we then classified the detected loads
as low (<500 conidia·g−1 sputum), intermediate (500–2000 conidia·g−1 sputum) or high (>2000 conidia·g−1
sputum). Measured conidial burden varied among Aspergillus-positive patients, and was comparable
between patients recruited from Singapore/Kuala Lumpur and Dundee (figure 5a). Interestingly, where
patients harboured both species concurrently, their proportionality varied: patients from sites in
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of stable bronchiectasis. a) Genus-level classification of the pulmonary mycobiome in nondiseased (n=10),
stable bronchiectasis (n=238), and matched SG/KL (n=100) and Dundee (n=100) cohorts. The relative
abundance of identified taxa is colour-coded. b) Percent prevalence of observed fungal genera (present at
>1% relative abundance) in matched bronchiectasis cohorts from SG/KL (n=100) and Dundee (n=100).
Significant differences in prevalence between cohorts are indicated. **: p<0.01; ***: p<0.001.
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Singapore/Kuala Lumpur exhibited higher proportions of A. fumigatus (median 69% of conidial load),
while the Dundee cohort had a higher A. terreus burden (median 89% of total conidial load) (figure 5b).
This agrees with our earlier observation of regional variation, where cohorts in Singapore/Kuala Lumpur
tended toward more A. fumigatus and the Dundee cohort greater A. terreus either when the fungi exist
alone or together. When patients were grouped by detectable Aspergillus species and accompanying
conidial burden (using high load as cut-off ), a significant association existed between high concurrent
conidial burdens of both Aspergillus species and greater exacerbations (figure 5c). Specifically, however,
when a high conidial burden of A. terreus was identified, either alone or in combination with
A. fumigatus, significantly more exacerbations also occurred (figure 5c).
A high frequency of clinically relevant Aspergillus-associated disease occurs in bronchiectasis
Prior work from our group and others highlights the association of Aspergillus-associated disease
(aspergillosis) with adverse clinical outcomes across a range of chronic respiratory diseases [7, 13, 22].
Given the high frequencies of Aspergillus detected, we next evaluated the occurrence of aspergillosis and its
clinical relevance in bronchiectasis. To do this, we used a modified immunological classification system
developed for CF (supplementary table E4) [14]. In addition to the criteria described by BAXTER et al. [14],
our modified version includes incorporation of potential A. terreus-associated disease (by inclusion of
A. terreus specific IgE and qPCR) along with other minor modifications detailed in supplementary table E4.
Of note, although total IgE was measured, it was not used in our classification of patients because it has
been described that ABPA may occur at IgE concentrations below the described cut-offs in the established
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year preceding study recruitment in patients with qPCR-detectable A. fumigatus (left) and A. terreus (right). c) Classification of qPCR-detectable
Aspergillus species by percentage of the total bronchiectasis patient cohort (n=238). Patients are classified as having no detectable species (n=39),
A. fumigatus only (n=26), A. terreus only (n=78) or both A. fumigatus and A. terreus (n=95). d) Exacerbations for the year preceding study
recruitment in patients with no detectable species, A. fumigatus only, A. terreus only or both A. fumigatus and A. terreus. Median number of
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criteria [23]. Patients were grouped into the following five categories: nondiseased (ND),
Aspergillus-colonised (AC), Aspergillus-sensitised (AS), serological ABPA (sABPA) and suspected chronic
pulmonary aspergillosis (sCPA). Significant numbers in the CAMEB cohort met criteria for an
Aspergillus-associated disease state (ND 1.7%, AC 3.4%, AS 76.5%, sABPA 18.1% and sCPA 0.3%) (figure 6).
Measured total serum IgE, Aspergillus specific IgG and sputum galactomannan varied between patient
groups (supplementary figure E1). Specific IgE against crude antigens of A. fumigatus and A. terreus,
respectively, was highest in AS (0.77 and 0.57 kU·L−1) and sABPA (0.92 and 0.93 kU·L−1) (p<0.001)
(figure 6a and b). TARC (thymus and activation regulated chemokine), previously identified as a marker
of CF-ABPA, was also assessed [24]. We found TARC to be a poor indicator of AS and/or sABPA in
bronchiectasis, with high false-negative rates in both groups (figure 6c). Additionally, false positives were
also observed in a small number of ND patients (figure 6c). Patients with sABPA exhibited significantly
more exacerbations, poorer pulmonary function and the severest disease compared with other groups
(figure 6d and f). AS was associated with greater exacerbations, while AC portended toward more
exacerbations with preserved pulmonary function and less severe disease (figure 6d and f). The AC, AS
and sABPA states therefore appear to exist along an increasing continuum of disease severity. Only a
single patient met criteria for sCPA, precluding further analysis of this group. Aspergillus-associated
disease in bronchiectasis is therefore frequent, variable and clinically relevant, including in patients
appearing clinically stable (a characteristic inclusion criteria for our study).
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FIGURE 5 Quantification of airway Aspergillus conidial burden and its association with exacerbations in
bronchiectasis (n=238). SG/KL: Singapore/Kuala Lumpur. a) Conidial burden per gram of sputum was
quantified for A. fumigatus and A. terreus, respectively, and classified according to load as low
(<500 conidia·g−1 sputum), intermediate (“Int.”; 500–2000 conidia·g−1 sputum) or high (>2000 conidia·g−1
sputum). Conidial load categories are illustrated according to fungal airway status as A. fumigatus only,
A. terreus only or the presence of both species. b) Scatter plot of A. fumigatus (x-axis) and A. terreus (y-axis)
conidial load in stable bronchiectasis. Patients with single and both species are indicated. Patients with both
species are classified by their relative A. fumigatus and A. terreus burdens into low burden of both (“LL”), low
burden of A. fumigatus and high burden of A. terreus (“LH”), high burden of A. fumigatus and low burden of
A. terreus (“HL”), and high burden of both (“HH”). Dotted lines indicate cut-off levels for a high conidial
burden (>2000 conidia·g−1 sputum). c) Exacerbations for the year preceding study recruitment in
bronchiectasis patients with detectable conidial burdens of both A. fumigatus and A. terreus as classified as
in (b). Median number of exacerbations per group is indicated and Benjamini–Hochberg adjusted p-values for
all groups compared with “None” are shown. *: p=0.01; **: p=0.006.
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Aspergillus-associated disease in bronchiectasis has distinct mycobiome profiles
As high frequencies of Aspergillus-associated disease were observed in bronchiectasis based on our
modified classification system, we next assessed for the presence of distinct taxonomic profiles that may
associate with four of the five clinical states: ND, AC, AS and sABPA, excluding sCPA because this group
contained only a single patient. Although unsupervised β diversity analysis revealed three distinct mycobiome
groups (supplementary figure E3), their association with clinical phenotype was not evident. We therefore
adopted a supervised strategy comparing mycobiome profiles between our identified immunological
classes. Each clinical state revealed mycobiome profiles characterised by a combination of varying fungal
genera (figure 7). The ND group exhibited apparent high abundance of Phellinus, Magnusiomyces
and Phlebia, with lower relative abundance of Saccharomyces, Aspergillus and Penicillium (figure 7a).
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FIGURE 6 Immunological classification reveals high frequencies of aspergillosis in stable bronchiectasis and
an association of serological allergic bronchopulmonary aspergillosis (sABPA) with greater exacerbations,
poorer pulmonary function and more severe disease. SG/KL: Singapore/Kuala Lumpur; ND: nondiseased;
AC: Aspergillus-colonised; AS: Aspergillus-sensitised; sCPA: suspected chronic pulmonary aspergillosis;
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Severity Index. a, b) Measured levels of specific IgE responses to a) A. fumigatus and b) A. terreus, where
aspergillosis is classified immunologically as ND (n=4), AC (n=8), AS (n=182), sABPA (n=43) and sCPA (n=1)
(supplementary table E4). c) TARC, a proposed ABPA marker in cystic fibrosis [24], was assessed according to
the same classification. Dashed lines show respective cut-offs indicating a positive test for each marker
(specific IgE 0.35 kU·L−1; TARC 386 pg·mL−1). d) Exacerbations for the year preceding study recruitment,
e) pulmonary function (FEV1 % pred) and f) disease severity (BSI) were assessed according to immunological
aspergillosis class. Mean values are indicated except for exacerbations and BSI, where median values are
shown. *: p<0.05; **: p<0.01; ***: p<0.001.
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These latter three genera, however, increased in their relative abundance across a spectrum from ND to
AC, AS and sABPA (figure 7 and supplementary table E5). The genera Cryptococcus and Clavispora
followed similar and comparable spectra, with increasing relative abundance from AC, AS to sABPA.
Mycosphaerella and Botrytis were present only in diseased states without a specific pattern (figure 7b and
d). Other characteristic fungal genera included Trichosporon and Cladosporium in the AC state, and
Wickerhamomyces and Alternaria in the AS and sABPA states (figure 7b). Importantly, the relative
abundance of Aspergillus detected from mycobiome profiles was in agreement with our qPCR-based
quantification of conidial burden for A. fumigatus and A. terreus across all disease categories, with greater
exacerbations noted in AS and sABPA (figure 7). Mycobiome profiles unique to each
Aspergillus-associated disease state are therefore potentially useful for future bronchiectasis studies that
focus on the diagnosis and endo-phenotyping of fungal disease.
Discussion
We describe the first, culture-independent analysis of the pulmonary mycobiome performed to date in
bronchiectasis and, to the best of our knowledge, the first such respiratory study to meticulously match
geographically distinct patient cohorts allowing us to assess potential regional variation in the mycobiome.
By applying high-throughput 18S–28S ITS sequencing and other molecular techniques, we delineated the
mycobiome constituents and their associated clinically relevant states. Our analysis identified Aspergillus as
a major fungal genus in bronchiectasis, similar to that described in other chronic respiratory diseases [6, 12].
An interesting observation was the prevalence of specific Aspergillus species characterising our Singapore/
Kuala Lumpur and Dundee cohorts, with A. fumigatus and A. terreus most frequently detected within each
respective group, the latter associated to exacerbations. Further patient stratification into groups including
AC, AS and sABPA states revealed high occurrences of clinically significant disease, even in “stable” patients,
and the existence of distinct mycobiome profiles of discriminant taxa for each group.
Changes to regional lung growth conditions create a conducive environment for colonisation and infection
by pathogenic microbes [2]. Given the gross anatomical distortion characteristic of bronchiectasis, it is
therefore unsurprising that microbial differences are observed when compared with nondiseased states.
The chronic bronchial insult coupled to anatomical distortion, compromised mucociliary clearance,
sustained neutrophilic response and recurrent infection all favour the growth of pathogenic fungi and their
ensuing clinical consequences in bronchiectasis [6, 25].
As observed in this and other studies, the airway mycobiome is dominated by Ascomycota [26].
Ascomycota-dominant profiles are characteristic of bronchiectasis, although an important minority have
high airway Basidiomycota. Basidiospores are environmentally more abundant and smaller than
ascospores, explaining their airway presence [27]. Compared with Ascomycota, which includes the
established respiratory pathogens Aspergillus and Candida, the specific role of Basidiomycota in
bronchiectasis is unclear. Notably, pathogenic Basidiomycota including Cryptococcus, Schizophyllum,
Phellinus, Ceriporia and Trichosporon were all detected in our work [28]. Cryptococcus is significantly
elevated in bronchiectasis, an observation previously documented that now warrants further investigation [29].
The existence of pulmonary Basidiomycota might reflect dynamic trafficking of “rare biosphere” fungi
(“immigration and elimination”), suggestive of a healthier respiratory state rather than the sustained fungal
outgrowth and unfavourable environment associated with Ascomycota [2, 5]. The cross-sectional design of
our study, however, precluded longitudinal assessment of the stability and transiency of the mycobiome over
time, a key consideration for future work.
Bronchiectasis-associated fungal genera include Aspergillus, Issatchenkia, Wickerhamomyces and
Simplicillium. Where dedicated species-specific qPCR for Aspergillus was performed, only A. fumigatus
and A. terreus were identifiable in bronchiectasis. Interestingly, A. fumigatus had a preponderance within
the Asian cohorts from Singapore/Kuala Lumpur, while A. terreus exhibited higher prevalence and burden
in patients from Dundee. Even in patients with both species, geographic origin dictated which
proportionally dominated. Our patients were stringently matched for age, sex and disease severity in order
FIGURE 7 Pulmonary mycobiome profiles illustrate specific taxa-associated patterns according to immunological classification of aspergillosis in
stable bronchiectasis. ND: nondiseased; AC: Aspergillus-colonised; AS: Aspergillus-sensitised; sABPA: serological allergic bronchopulmonary
aspergillosis. a) ND (n=4), b) AC (n=8), c) AS (n=182) and d) sABPA (n=43) mycobiome profiles illustrate the different composition by relative
abundance of reads classified to genus level, with the b) AC, c) AS and d) sABPA states exhibiting increased exacerbations and higher conidial
load. Only a single patient had sCPA and therefore data is not shown. Mycobiome profiles are represented by pie charts with colour coding
according to the taxonomic legend. Adjacent colour-coded log-scaled bar charts detail the observed taxa patterns in each immunological patient
class (formal statistical assessment is provided in supplementary table E5). Exacerbations in the preceding year (y-axis) are plotted against
Aspergillus conidial load (x-axis) and colour-coded according to quantitative PCR detection status of Aspergillus species into A. fumigatus alone,
A. terreus alone, presence of both or none. Patients are further classified according to their individual conidial load as negative (“Neg.”; no detected
conidia·g−1 sputum), low (<500 conidia·g−1 sputum), intermediate (“Int.”; 500–2000 conidia·g−1 sputum) or high (>2000 conidia·g−1 sputum).
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to confront the heterogeneity that plagues bronchiectasis research and allowed us to better assess potential
geographic variation. Studies of additional cohorts from Europe and Asia will be required to determine if
these are truly geographical differences or reflect differences in patient selection or referral patterns at the
participating sites. These geographic phenotypes were accompanied by differences in lung mycobiome
profiles: Penicillium, Clavispora and Cryptococcus had markedly higher frequency in patients from Dundee,
while Basidiomycota genera Phlebia, Trichosporon, Ceriporia, Phellinus, Schizophyllum, Psathyrella and
Peniophora were exclusive to patients from Singapore/Kuala Lumpur who exhibited higher overall
Basidiomycota. Our identified differences may reflect a myriad of regionally variable factors such as
contrasting atmospheric conditions between temperate and tropical climates including temperature and
humidity, each documented to affect fungi [30, 31]. Interestingly, our identified geographic variation of
A. terreus predominance in Dundee occurred despite low reported UK prevalence rates of this fungus,
suggestive of enrichment in the bronchiectasis population [32]. CF-related bronchiectasis also associates
with A. terreus and an unidentified “environmental exposure” of likely relevance in our Dundee cohort is
ascribed to this species [33, 34]. Other key geographic factors to consider include dietary preferences,
genetics, air quality and/or lifestyle, all influences on acquisition and persistence of microbes including
fungi [35]. Interestingly, the marked body mass index difference between our “matched” cohorts raises
questions about potential differences in gut microbiomes that in turn may associate with the airway
mycobiome given the emerging lung–gut axis relationship, an area of increasing relevance to respiratory
health [36]. Other confounders to consider include regional differences in pharmacological prescribing and
their consequent implications for the mycobiome. These are important considerations given differences
between our Dundee and Singapore/Kuala Lumpur cohorts in terms of inhaled corticosteroids, long-term
prophylactic antibiotics (greater in Dundee) and mucolytic use (greater in Singapore/Kuala Lumpur)
(table 1), all features of potential influence on mycobiome composition that warrant further study. While
our findings could be peculiar to Dundee, Singapore and Malaysia, generalisability is supported by data
showing that Dundee patients are similar and data generated in Scotland has been generalisable across
more than 10 European cohorts in recent analyses [37, 38].
Our group and others have previously investigated the role of Aspergillus-associated disease in CF-related
bronchiectasis, although focused work in non-CF bronchiectasis is lacking [7, 35, 39–41]. Importantly,
however, EVERAERTS et al. [22] assessed the occurrence of A. fumigatus sensitisation in COPD and, when
detectable, associated it with a high risk for bronchiectasis. These data support the role for Aspergillus as a
bronchiectasis pathogen either as a cause or consequence. Our data further corroborate such associations with
high observable specific IgE levels to A. fumigatus and A. terreus. Using a modified immunological
classification, adapted from CF, we describe high rates of AS and sABPA disease states in the CAMEB cohort,
outlining its clinical relevance even in patients appearing clinically stable [14]. TARC, a proposed marker of
CF-ABPA, was found to have poor sensitivity and specificity when applied to the CAMEB cohort, illustrating
difficulties in translating findings from CF to non-CF bronchiectasis [24]. Each of our classified clinical states
is accompanied by a distinct mycobiome pattern suggestive of mechanistic links necessitating future studies.
A potential role for A. terreus in bronchiectasis is a novel finding of this work. When compared with
A. fumigatus, A. terreus is less studied. It is, however, noted for colonising the CF lung, is capable of causing
ABPA and associates with opportunistic infections [42–44]. Its resistance to polyene antifungals confers
survival advantages in the host compared with A. fumigatus [45, 46]. Although A. terreus conidia are rapidly
phagocytosed through their recognition by dectin-1 and mannose receptors, they exhibit increased
macrophage survival compared with A. fumigatus [46]. Rapid germination of A. fumigatus within the
macrophage comes at the cost of its increased vulnerability to host immunity. In contrast, A. terreus
germinates at lower rates favouring its persistence. Our work highlights high proportions of bronchiectasis
patients with both A. fumigatus and A. terreus. Moreover, such patients demonstrate greater exacerbations,
suggestive that in combination these fungi have important clinical effects on distinct host pathways that worsen
disease. As a consequence, assessment of fungal airway conidial burden is important in bronchiectasis.
While our work is novel, it does have limitations including its cross-sectional design. This is a
consequence of our attempt to robustly match Asian and European cohorts within the study to address
disease heterogeneity, a key issue in bronchiectasis research. In addition, we must consider the
“generalisability” of our three participating countries in comparison to the wider Asian and European
subcontinents, including the potential variation in aetiology for exacerbations, their management including
bronchiectasis treatments, and geographic differences in climate, temperature and air quality.
Epidemiological fungal studies have in fact illustrated species differences between countries even within the
same subcontinent [32]. Furthermore, we included only a small group of nondiseased (healthy) individuals
(all from Singapore) that precluded us from defining a “healthy” mycobiome clearly, which was not the
primary aim of this work. Future studies, however, should focus on assessing the nondiseased lung
mycobiome and include individuals from more than a single region to assess potential geographic
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variation. In addition, targeted amplicon sequencing, even through our parallel shotgun sequencing of
ITS1 and ITS2, has lower resolution compared with the more costly and analytically challenging
whole-genome shotgun metagenomics approach that provides superior speciation and functional
annotation. We focused on Aspergillus as the predominant bronchiectasis-associated fungal pathogen;
however, our mycobiome analysis suggests that other fungal genera may also have roles. Finally, when the
CAMEB cohort was conceived, a decision was made to match across Singapore/Kuala Lumpur and
Dundee based on age, sex and disease severity. This matching on total BSI rather than its specific
components, including exacerbations, radiology or microbiology, limits our ability to perform more
specific analyses. Our cohort enrolled predominantly severe patients with bronchiectasis with a relatively
low number of patients with mild disease (BSI 0–4).
In conclusion, we have performed the first fungal profiling study in bronchiectasis to date using two
“matched” cohorts across three countries. We illustrate high levels of airway fungi and key differences
between cohorts. These data suggest that the role for fungi, and specifically Aspergillus, in bronchiectasis is
significant and routine screening for Aspergillus-associated diseases should be considered for inclusion in
future bronchiectasis guidelines. Screening may include skin testing, Aspergillus-associated specific IgE and
Aspergillus specific IgG with potential follow-up immunological monitoring for those clinically affected.
Our identified mycobiome profiles that relate to clinical disease should also be elucidated in future work.
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